… The indication of afatinib and erlotinib for SqCC of the lung had not been approved.
However, because the oncologist and patients would still pursue these agents as second-line …

… that with erlotinib across patient subgroups in this secondary … erlotinib treatment was more
pronounced among patients … without, especially among patients with tumors having HER2 or …

… Thus, our subanalyses confirm existing evidence that for EGFR wild-type patients, first-line
erlotinib produces inferior clinical efficacy and inferior quality of life outcomes compared with …

… of erlotinib as a second-line treatment in PS0/1 patients. In PS2 patients, erlotinib was inferior
… favorable therapeutic option for EGFR mutation-negative patients in a second line setting. …

… Second progression-free survival was calculated from … second line of treatment if the patient
received 2 lines, or after the first line if the patient progressed and did not receive a second …

… Therefore, the survival signal of our combination should be investigated in future studies in
HCC patients in the second-line treatment setting in the USA, focusing on biomarker studies …

… second-line treatment. We aimed to evaluate the efficacy and safety of erlotinib monotherapy
as third-line chemotherapy in patients … -line erlotinib for patients without EGFR mutations. …

… Forty (87%) patients had adenocarcinoma and 22 (… Erlotinib administered in the current
study was second-line treatment for half of the 46 patients recruited and the proportion of patients …

… Patients failing or unsuitable for chemotherapy or radiotherapy received erlotinib 150 mg/…
We examined a subpopulation of elderly patients (≥70 years) receiving first-line erlotinib (n=…

… benefits than erlotinib monotherapy in previously treated patients with advanced NSCLC. …
of everolimus and erlotinib for second- and third-line combination therapy in patients with …